Innova Biosciences introduces range of conjugated antibodies
Innova Biosciences (Innova), a specialist provider of bioconjugation products and services, announced today the launch of a range of conjugated antibodies. The unique range leverages Innova’s Lightning-Link® and InnovaCoat® bioconjugation technologies, to provide customers with antibodies conjugated to an extensive range of enzymes, fluorescent dyes and colloidal gold, for improved flexibility in…
Innova Biosciences and Mologic sign supply and licensing agreement
Innova Biosciences (Innova), a specialist provider of bioconjugation products and services, and Mologic, a specialist diagnostic development company and molecular reagent innovator, announced today the signing of a supply and licensing agreement for use of Innova’s Lightning-Link® and InnovaCoat® GOLD technologies as part of Mologic’s commercial assay development services and range of…
Dr Jane Osbourn joins Babraham Bioscience Technologies as new Non-Executive Director
Babraham Bioscience Technologies Ltd (BBT), which develops and manages the Babraham Research Campus, announced today that Dr Jane Osbourn, VP R&D and Site Leader of MedImmune in Cambridge, has joined the board as a non-executive director.
Rapid Biosensor moves into pneumonia diagnostic testing at Point-of-Care
Rapid Biosensor Systems Ltd (Babraham Research Campus, Cambridge) is developing a rapid test for bacterial pneumonia by adapting its successful TB Breathalyser product, which has been endorsed by Medics in India and Ethiopia after field trials on nearly 1,000 people.
Imperial College creates opportunities for spin-outs to grow at Babraham
Imperial College London is to invest in a new facility at the Babraham Research Campus in Cambridge to support spin-out and scale-up companies, and maximise the impact of research from universities.
Babraham Research Campus: Fifteen to Fifty
With the first commercial tenant at the Babraham Research Campus in 1998, Babraham Bioscience Technologies (BBT) Limited celebrates its fifteenth anniversary this year.
Babraham’s Biotechnology Investment Forum 2013 is deemed a great success
The annual event which brings together early-stage bioscience companies and potential investors has been organised by Babraham Bioscience Technologies on the Babraham Research Campus by since 2006. Twelve companies made presentations to over 40 angel, VC and corporate investors.
Cancer Research Technology moves into newly completed Jonas Webb Building
Babraham Bioscience Technologies (BBT) has announced that Cancer Research Technology Limited (CRT), the cancer-focused technology development and commercialisation arm of Cancer Research UK, has moved its Cambridge drug discovery activity into a new chemistry-focused building on the Babraham Research Campus. The new building has been named ‘The Jonas Webb Building’.
Andes Charity Challenge raises money for Macmillan Cancer Support
Inspired by a local businessman’s plans to raise £100k for Macmillan Cancer Support, tackling the toughest mountain in South America – Babraham Bioscience Technologies (BBT) Ltd has joined forces with the contractors currently developing the Babraham Research Campus, to take Mr Roger Parker closer to his target.
Babraham joins forces with Cambridge University's ideaSpace to accelerate enterprise
The Babraham Research Campus and Cambridge University's ideaSpace have entered into a strategic relationship through which early-stage ventures will have dual access to the ‘plug and play’ laboratory facilities at Babraham and the co-working community at the ideaSpace in the Hauser Forum.